RT Journal Article SR Electronic T1 ▾ Sumatriptan: a new approach to migraine JF Drug and Therapeutics Bulletin JO Drug Ther Bull FD BMJ Publishing Group Ltd SP 85 OP 87 DO 10.1136/dtb.30.22.85 VO 30 IS 22 YR 1992 UL http://dtb.bmj.com/content/30/22/85.abstract AB Last year subcutaneous sumatriptan (Imigran – Glaxo) was introduced in Britain as “a revolutionary acute therapy in migraine”. The claims were repeated when an oral preparation was launched earlier this year. Sumatriptan is licensed for the acute relief of migraine attacks with or without aura; the subcutaneous preparation is also licensed for the treatment of cluster headache.